Future of First-in-Class Roxadustat for Lower-Risk MDS Remains Uncertain
The phase III MATTERHORN trial comparing roxadustat with placebo in patients with transfusion-dependent, lower-risk myelodysplastic syndromes (MDS) failed to meet ...
Molecular Taxonomy of MDS May Help Guide Clinical Decisions, Trials
In patients with myelodysplastic syndromes/neoplasms (MDS), genomic profiling identified molecular subgroups associated with specific clinical phenotypes and disease ...
Study of Patients with Myelodysplastic Syndromes Questions Need for Induction Therapy Before AlloHCT
Some patients with myelodysplastic syndromes (MDS) receive therapy before an allogeneic hematopoietic cell transplant (alloHCT) to improve their Revised International Prognostic Scoring System ...
Decision Support System Defines Optimal Transplant Timing for Patients with Myelodysplastic Syndromes
A new clinical and genetics-based decision strategy shows how patients with low- and moderate-low risk myelodysplastic syndromes (MDS), according to the Molecular Revised International Prognostic Scoring System ...
Safety of Oral Azacytidine in Patients With Lower-Risk MDS Consistent With Prior Results
Two lower doses of oral azacytidine (oral-AZA [CC-486]) are safe for patients with lower- and intermediate-risk myelodysplastic syndromes (MDS), according to the results of the phase II/III ASTREON study ...
Imetelstat Produces RBC Transfusion Independence in Lower-Risk Myelodysplastic Syndromes
The competitive telomerase inhibitor imetelstat produced prolonged independence from red blood cell (RBC) transfusions in a considerable number of patients with lower-risk myelodysplastic syndromes ...
Data-Driven Analysis Harmonizes 2022 WHO, ICC Classifications of Myelodysplastic Syndromes
In 2022, the World Health Organization (WHO) and the International Consensus Classification (ICC) introduced gene mutations and chromosomal abnormalities into their distinct classifications of ...
TRANSFORM-1 Trial of Navitoclax in Combination With Ruxolitinib for Myelofibrosis Met Primary but not Secondary Endpoint
The phase III results of TRANSFORM-1, the first randomized trial of navitoclax plus ruxolitinib in Janus kinase (JAK) inhibitor-naïve patients with myelofibrosis ...
Vibecotamab Shown to Be Effective Treatment for MDS, CMML
A phase II study has found vibecotamab an active treatment with a predictable side effect profile for low-blast, high-risk myeloid neoplasia ...
Pelabresib, Ruxolitinib Combination Improves Spleen Response in Myelofibrosis
The combination of pelabresib plus ruxolitinib significantly improved spleen volume reduction (SVR) at week 24 among patients with Janus kinase inhibitor (JAKi)-naïve primary myelofibrosis ...
